Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Oncology Report

• Publication date

  2012-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.3892/or.2012.1743PMID 22469881PMCID PMC4028227
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sphingosine kinase: A promising cancer therapeutic target

  2011cited by this paper
• Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2

  2011cited by this paper
• Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.

  2011cited by this paper
• Novel d-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics

  2010cited by this paper
• Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

  2010cited by this paper
• Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells.

  2009cited by this paper
• Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max).

  2009cited by this paper
• Sphingolipids as Determinants of Apoptosis and Chemoresistance in the MCF-7 Cell Model System

  2009cited by this paper
• Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase.

  2008cited by this paper
• Identification of Key Processes Underlying Cancer Phenotypes Using Biologic Pathway Analysis

  2007cited by this paper
• Antitumor Activity of Sphingosine Kinase Inhibitors

  2006cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases.

  2006cited by this paper
• Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory mediators.

  2005cited by this paper
• SphK1 and SphK2, Sphingosine Kinase Isoenzymes with Opposing Functions in Sphingolipid Metabolism*

  2005cited by this paper
• Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation.

  2005cited by this paper
• Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.

  2004cited by this paper
• Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer

  2004cited by this paper
• Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import.

  2004cited by this paper
• Signaling to NF-kappaB.

  2004cited by this paper
• Discovery and evaluation of inhibitors of human sphingosine kinase.

  2003cited by this paper
• Sphingosine Kinase Interacts with TRAF2 and Dissects Tumor Necrosis Factor-α Signaling*

  2002cited by this paper
• Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray.

  2002cited by this paper
• Series introduction: the transcription factor NF-kappaB and human disease.

  2001cited by this paper
• Nuclear factor-kappa B, cancer, and apoptosis.

  2000cited by this paper
• NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1

  1999cited by this paper
• Apoptosis, p53, and tumor cell sensitivity to anticancer agents.

  1999cited by this paper
• Activation of Sphingosine Kinase by Tumor Necrosis Factor-α Inhibits Apoptosis in Human Endothelial Cells*

  1999cited by this paper
• Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants.

  1998cited by this paper
• Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway.

  1998cited by this paper
• Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth

  1997cited by this paper
• Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.

  1997cited by this paper
• Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component.

  1996cited by this paper
• The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression.

  1996cited by this paper
• Sphingolipid metabolism and cell growth regulation

  1996cited by this paper

• Deciphering the molecular interplay of sphingosine kinase 1 (SPHK1) signaling in cancer drug resistance and therapeutic targeting

  2025cites this paper
• Sphingosine-1-Phosphate Metabolic Pathway in Cancer: Implications for Therapeutic Targets

  2025cites this paper
• Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy

  2024cites this paper
• Role of Sphingosine-1-Phosphate Signaling Pathway in Pancreatic Diseases

  2024cites this paper
• The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance

  2022cites this paper
• Targeting Sphingolipids for Cancer Therapy

  2021cites this paper
• Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments.

  2019cites this paper
• Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target.

  2019cites this paper
• Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells

  2019cites this paper
• Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming

  2018cites this paper
• Inhibition of breast tumor growth in mice after treatment with ceramide analog 315

  2018cites this paper
• CONCENTRATION OF CERAMIDE KINASE (CER) AS ASSAY TO MEASURE CELLULAR LEVELS OF CERAMIDE IN SERUM AND TISSUE BY USING ELIZA TECHNIQUE IN BPH, PC, AND HEALTHY MEN IN IRAQ.

  2017influential citation
• A promising anti-cancer agent that functions as a dual target inhibitor of SphK1 and microtubule dynamics

  2016cites this paper
• Recent advances in the development of sphingosine kinase inhibitors.

  2016cites this paper
• Elevated expression of long intergenic non‐coding RNA HOTAIR in a basal‐like variant of MCF‐7 breast cancer cells

  2015cites this paper
• Sphingosine kinases signalling in carcinogenesis.

  2015cites this paper
• Expression levels of bioactive sphingolipid genes in newly diagnosed and drug-resistant chronic myeloid leukemia patients and their impact on the clinical progress

  2015cites this paper
• Sphingosine-1-phosphate (S1P) in cancer immunity and development

  2015cites this paper
• Role of sphingolipids in oestrogen signalling in breast cancer cells: an update.

  2014influential citation
• Re-Configuration of Sphingolipid Metabolism by Oncogenic Transformation

  2014cites this paper
• Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

  2014cites this paper
• Retinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat-diet

  2013cites this paper
• Novel chemotherapeutic drugs in sphingolipid cancer research.

  2013cites this paper
• Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition

  2013cites this paper
• Sphingolipids in apoptosis.

  2012cites this paper
• Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance

  2012cites this paper
• Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.

  2012cites this paper
• Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer

  2012cites this paper
• Novel agents targeting bioactive sphingolipids for the treatment of cancer.

  2012cites this paper